Precipio, Inc.
About Precipio, Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $24.2M
- Net income
- -$363.0K
- Total assets
- $21.3M
- Market cap
- $42.0M
- Gross margin
- 44.5%
- Operating margin
- -5.0%
- Net margin
- -1.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $24.0M
- Cost of revenue
- $13.3M
- Gross profit
- $10.7M
- Operating expenses
- $11.9M
- Operating income
- -$1.2M
- Income tax
- $0
- Net income
- -$363.0K
- EPS (basic)
- $-0.23
- EPS (diluted)
- $-0.23
Balance sheet
- Total assets
- $21.3M
- Current assets
- $6.0M
- Total liabilities
- $6.8M
- Current liabilities
- $3.8M
- Shareholders’ equity
- $14.6M
Cash flow
- Operating cash flow
- $685.0K
- Investing cash flow
- -$326.0K
- Financing cash flow
- $903.0K
- Net cash flow
- $1.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $42.0M
- EPS (diluted)
- $-0.23
- Shares outstanding
- 1.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 18, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $363.0K in FY2025.
- Revenue grew 172% from FY2021 to FY2025.
- Gross margin of 44.5%, net margin -1.5%.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Precipio, Inc..
Write a review
News about Precipio, Inc.
News & sentiment via Polygon.io
